350 related articles for article (PubMed ID: 26782663)
1. Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.
Spelman T; Mekhael L; Burke T; Butzkueven H; Hodgkinson S; Havrdova E; Horakova D; Duquette P; Izquierdo G; Grand'Maison F; Grammond P; Barnett M; Lechner-Scott J; Alroughani R; Trojano M; Lugaresi A; Granella F; Pucci E; Vucic S;
Eur J Neurol; 2016 Apr; 23(4):729-36. PubMed ID: 26782663
[TBL] [Abstract][Full Text] [Related]
2. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
4. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.
Kister I; Spelman T; Alroughani R; Lechner-Scott J; Duquette P; Grand'Maison F; Slee M; Lugaresi A; Barnett M; Grammond P; Iuliano G; Hupperts R; Pucci E; Trojano M; Butzkueven H;
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1133-7. PubMed ID: 27298148
[TBL] [Abstract][Full Text] [Related]
5. Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial.
Ozakbas S; Cinar BP; Kosehasanoğullari G; Kahraman T; Oz D; Kursun BB
Clin Neurol Neurosurg; 2017 Sep; 160():69-72. PubMed ID: 28689102
[TBL] [Abstract][Full Text] [Related]
6. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
[TBL] [Abstract][Full Text] [Related]
7. Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry.
Stuchiner T; Lucas L; Baraban E; Spinelli KJ; Chen C; Smith A; Hashemi L; Cohan S
BMC Neurol; 2020 Dec; 20(1):439. PubMed ID: 33272224
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry.
Spelman T; Frisell T; Piehl F; Hillert J
Mult Scler; 2018 Jul; 24(8):1087-1095. PubMed ID: 28649912
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina.
Carrá A; Onaha P; Luetic G; Burgos M; Crespo E; Deri N; Halfon M; Jaacks G; López A; Sinay V; Vrech C
Eur J Neurol; 2008 Apr; 15(4):386-93. PubMed ID: 18353125
[TBL] [Abstract][Full Text] [Related]
10. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
[TBL] [Abstract][Full Text] [Related]
11. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
[TBL] [Abstract][Full Text] [Related]
13. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.
Kalincik T; Jokubaitis V; Izquierdo G; Duquette P; Girard M; Grammond P; Lugaresi A; Oreja-Guevara C; Bergamaschi R; Hupperts R; Grand'Maison F; Pucci E; Van Pesch V; Boz C; Iuliano G; Fernandez-Bolanos R; Flechter S; Spitaleri D; Cristiano E; Verheul F; Lechner-Scott J; Amato MP; Cabrera-Gomez JA; Saladino ML; Slee M; Moore F; Gray O; Paine M; Barnett M; Havrdova E; Horakova D; Spelman T; Trojano M; Butzkueven H;
Mult Scler; 2015 Aug; 21(9):1159-71. PubMed ID: 25480857
[TBL] [Abstract][Full Text] [Related]
15. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
de Flon P; Gunnarsson M; Laurell K; Söderström L; Birgander R; Lindqvist T; Krauss W; Dring A; Bergman J; Sundström P; Svenningsson A
Neurology; 2016 Jul; 87(2):141-7. PubMed ID: 27316241
[TBL] [Abstract][Full Text] [Related]
16. Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register.
D'Amico E; Zanghì A; Romeo M; Cocco E; Maniscalco GT; Brescia Morra V; Paolicelli D; De Luca G; Galgani S; Amato MP; Salemi G; Inglese M; Confalonieri PA; Lus G; Avolio C; Gallo A; Vianello M; Onofrj M; Filippi M; Trojano M; Patti F
Neurotherapeutics; 2021 Apr; 18(2):905-919. PubMed ID: 33528815
[TBL] [Abstract][Full Text] [Related]
17. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.
Bergvall N; Makin C; Lahoz R; Agashivala N; Pradhan A; Capkun G; Petrilla AA; Karkare SU; McGuiness CB; Korn JR
PLoS One; 2014; 9(2):e88472. PubMed ID: 24516663
[TBL] [Abstract][Full Text] [Related]
18. Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
Guger M; Enzinger C; Leutmezer F; Di Pauli F; Kraus J; Kalcher S; Kvas E; Berger T;
J Neurol; 2023 Jun; 270(6):3103-3111. PubMed ID: 36862148
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
Khan O; Rieckmann P; Boyko A; Selmaj K; Ashtamker N; Davis MD; Kolodny S; Zivadinov R
Mult Scler; 2017 May; 23(6):818-829. PubMed ID: 27503905
[TBL] [Abstract][Full Text] [Related]
20. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
